<VariationArchive VariationID="3244689" VariationName="NC_000011.9:g.(?_32410601)_(32421600_?)del" VariationType="Deletion" Accession="VCV003244689" Version="1" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-07-07" DateCreated="2024-06-30" MostRecentSubmission="2024-06-29">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="3402053" VariationID="3244689">
      <GeneList>
        <Gene Symbol="WT1" FullName="WT1 transcription factor" GeneID="7490" HGNC_ID="HGNC:12796" Source="calculated" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>11p13</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="11" Accession="NC_000011.10" start="32387775" stop="32435539" display_start="32387775" display_stop="32435539" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="11" Accession="NC_000011.9" start="32409320" stop="32457080" display_start="32409320" display_stop="32457080" Strand="-" />
          </Location>
          <OMIM>607102</OMIM>
          <Haploinsufficiency last_evaluated="2022-01-25" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=WT1">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2022-01-25" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=WT1">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NC_000011.9:g.(?_32410601)_(32421600_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>11p13</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="11" Accession="NC_000011.9" innerStart="32410601" innerStop="32421600" display_start="32410601" display_stop="32421600" variantLength="11000" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000011.9" sequenceAccession="NC_000011" sequenceVersion="9" change="g.(?_32410601)_(32421600_?)del" Assembly="GRCh37">
            <Expression>NC_000011.9:g.(?_32410601)_(32421600_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000011.9:g.(?_32410601)_(32421600_?)del AND multiple conditions" Accession="RCV004580276" Version="1">
        <ClassifiedConditionList TraitSetID="31140">
          <ClassifiedCondition DB="MedGen" ID="C0206115">11p partial monosomy syndrome</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0950121">Drash syndrome</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0950122">Frasier syndrome</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="CN033288">Wilms tumor 1</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-12-26" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2022-12-26" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2024-06-30" MostRecentSubmission="2024-06-29">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">10571943</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">12471221</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">15150775</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">21508141</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">21851196</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">23117548</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">23515051</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">9108089</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="31140" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="4506" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Wilms tumor, somatic</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Wilms tumor 1</ElementValue>
                <XRef ID="MONDO:0008679" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">WT1</ElementValue>
                <XRef Type="MIM" ID="194070" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="15124" />
                <XRef ID="15124" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">PAX6-related aniridia occurs either as an isolated ocular abnormality or as part of the Wilms tumor-aniridia-genital anomalies-retardation (WAGR) syndrome. Aniridia is a pan ocular disorder affecting the cornea, iris, intraocular pressure (resulting in glaucoma), lens (cataract and lens subluxation), fovea (foveal hypoplasia), and optic nerve (optic nerve coloboma and hypoplasia). Individuals with aniridia characteristically show nystagmus and impaired visual acuity (usually 20/100 - 20/200); however, milder forms of aniridia with subtle iris architecture changes, good vision, and normal foveal structure do occur. Other ocular involvement may include strabismus and occasionally microphthalmia. Although the severity of aniridia can vary between and within families, little variability is usually observed in the two eyes of an affected individual. WAGR syndrome. The risk for Wilms tumor is 42.5%-77%; of those who develop Wilms tumor, 90% do so by age four years and 98% by age seven years. Genital anomalies in males can include cryptorchidism and hypospadias (sometimes resulting in ambiguous genitalia), urethral strictures, ureteric abnormalities, and gonadoblastoma. While females typically have normal external genitalia, they may have uterine abnormalities and streak ovaries. Intellectual disability (defined as IQ &lt;74) is observed in 70%; behavioral abnormalities include attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder, anxiety, depression, and obsessive-compulsive disorder. Other individuals with WAGR syndrome can have normal intellect without behavioral problems.</Attribute>
                <XRef ID="NBK1360" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301471</ID>
                <ID Source="BookShelf">NBK1294</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301534</ID>
                <ID Source="BookShelf">NBK1360</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">32352694</ID>
                <ID Source="BookShelf">NBK556455</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/wilms_tumor.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN GuidelinesÂ®), Wilms Tumor (Nephroblastoma), 2023</CitationText>
              </Citation>
              <XRef ID="654" DB="Orphanet" />
              <XRef ID="CN033288" DB="MedGen" />
              <XRef ID="MONDO:0008679" DB="MONDO" />
              <XRef Type="MIM" ID="194070" DB="OMIM" />
            </Trait>
            <Trait ID="4509" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">11p partial monosomy syndrome</ElementValue>
                <XRef ID="11p+partial+monosomy+syndrome/7605" DB="Genetic Alliance" />
                <XRef ID="4135001" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">WAGR Complex</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Wilms Tumor-Aniridia-Gonadoblastoma-Mental Retardation syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Chromosome 11p deletion syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">11p deletion syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">CHROMOSOME 11p13 DELETION SYNDROME</ElementValue>
                <XRef Type="MIM" ID="194072" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">WAGR syndrome</ElementValue>
                <XRef ID="MONDO:0008681" DB="MONDO" />
                <XRef ID="893" DB="Orphanet" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">WAGR</ElementValue>
                <XRef Type="MIM" ID="194072" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">PAX6-related aniridia occurs either as an isolated ocular abnormality or as part of the Wilms tumor-aniridia-genital anomalies-retardation (WAGR) syndrome. Aniridia is a pan ocular disorder affecting the cornea, iris, intraocular pressure (resulting in glaucoma), lens (cataract and lens subluxation), fovea (foveal hypoplasia), and optic nerve (optic nerve coloboma and hypoplasia). Individuals with aniridia characteristically show nystagmus and impaired visual acuity (usually 20/100 - 20/200); however, milder forms of aniridia with subtle iris architecture changes, good vision, and normal foveal structure do occur. Other ocular involvement may include strabismus and occasionally microphthalmia. Although the severity of aniridia can vary between and within families, little variability is usually observed in the two eyes of an affected individual. WAGR syndrome. The risk for Wilms tumor is 42.5%-77%; of those who develop Wilms tumor, 90% do so by age four years and 98% by age seven years. Genital anomalies in males can include cryptorchidism and hypospadias (sometimes resulting in ambiguous genitalia), urethral strictures, ureteric abnormalities, and gonadoblastoma. While females typically have normal external genitalia, they may have uterine abnormalities and streak ovaries. Intellectual disability (defined as IQ &lt;74) is observed in 70%; behavioral abnormalities include attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder, anxiety, depression, and obsessive-compulsive disorder. Other individuals with WAGR syndrome can have normal intellect without behavioral problems.</Attribute>
                <XRef ID="NBK1360" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="5528" />
                <XRef ID="5528" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301534</ID>
                <ID Source="BookShelf">NBK1360</ID>
              </Citation>
              <Citation Type="Translational/Evidence-based" Abbrev="EuroGenetest, 2011">
                <ID Source="pmc">3060328</ID>
              </Citation>
              <XRef ID="893" DB="Orphanet" />
              <XRef ID="C0206115" DB="MedGen" />
              <XRef ID="MONDO:0008681" DB="MONDO" />
              <XRef Type="MIM" ID="194072" DB="OMIM" />
            </Trait>
            <Trait ID="2150" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Frasier syndrome</ElementValue>
                <XRef ID="Frasier+Syndrome/2919" DB="Genetic Alliance" />
                <XRef ID="MONDO:0007635" DB="MONDO" />
                <XRef ID="445431000" DB="SNOMED CT" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="2375" />
                <XRef ID="2375" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">WT1 disorder is characterized by congenital/infantile or childhood onset of steroid-resistant nephrotic syndrome (SRNS), a progressive glomerulopathy that does not respond to standard steroid therapy. Additional common findings can include disorders of testicular development (with or without abnormalities of the external genitalia and/or mÃ¼llerian structures) and Wilms tumor. Less common findings are congenital anomalies of the kidney and urinary tract (CAKUT) and gonadoblastoma. While various combinations of renal and other findings associated with a WT1 pathogenic variant were designated as certain syndromes in the past, those designations are now recognized to be part of a phenotypic continuum and are no longer clinically helpful.</Attribute>
                <XRef ID="NBK556455" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">32352694</ID>
                <ID Source="BookShelf">NBK556455</ID>
              </Citation>
              <XRef ID="347" DB="Orphanet" />
              <XRef ID="C0950122" DB="MedGen" />
              <XRef ID="D052159" DB="MeSH" />
              <XRef ID="MONDO:0007635" DB="MONDO" />
              <XRef Type="MIM" ID="136680" DB="OMIM" />
            </Trait>
            <Trait ID="969" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Drash syndrome</ElementValue>
                <XRef ID="Wilms+tumor+and+pseudohermaphroditism/7503" DB="Genetic Alliance" />
                <XRef ID="236385009" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Nephropathy, wilms tumor, and genital anomalies</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Pseudohermaphroditism, nephron disorder and Wilms' tumor</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Nephropathy associated with male pseudohermaphroditism and Wilms' tumor</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">WILMS TUMOR AND PSEUDO- OR TRUE HERMAPHRODITISM</ElementValue>
                <XRef Type="MIM" ID="194080" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Wilms tumor and pseudohermaphroditism</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">DDS</ElementValue>
                <XRef Type="MIM" ID="194080" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="5576" />
                <XRef ID="5576" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">WT1 disorder is characterized by congenital/infantile or childhood onset of steroid-resistant nephrotic syndrome (SRNS), a progressive glomerulopathy that does not respond to standard steroid therapy. Additional common findings can include disorders of testicular development (with or without abnormalities of the external genitalia and/or mÃ¼llerian structures) and Wilms tumor. Less common findings are congenital anomalies of the kidney and urinary tract (CAKUT) and gonadoblastoma. While various combinations of renal and other findings associated with a WT1 pathogenic variant were designated as certain syndromes in the past, those designations are now recognized to be part of a phenotypic continuum and are no longer clinically helpful.</Attribute>
                <XRef ID="NBK556455" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">32352694</ID>
                <ID Source="BookShelf">NBK556455</ID>
              </Citation>
              <XRef ID="220" DB="Orphanet" />
              <XRef ID="C0950121" DB="MedGen" />
              <XRef ID="MONDO:0008682" DB="MONDO" />
              <XRef Type="MIM" ID="194080" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="9835202" SubmissionDate="2024-06-04" DateLastUpdated="2024-06-29" DateCreated="2024-06-29">
        <ClinVarSubmissionID localKey="NC_000011.9:g.(?_32410601)_(32421600_?)del|MedGen:CN033288;C0950121;CN206326;C0950122" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV005064279" DateUpdated="2024-06-29" DateCreated="2024-06-29" Type="SCV" Version="1" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-12-26">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">9108089</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">10571943</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">12471221</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">15150775</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21508141</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21851196</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23117548</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23515051</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the WT1 protein in which other variant(s) (p.Arg458*) have been determined to be pathogenic (PMID: 9108089, 10571943, 12471221, 15150775, 21508141, 21851196, 23117548, 23515051). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. This variant has not been reported in the literature in individuals affected with WT1-related conditions. This variant is a gross deletion of the genomic region encompassing exon(s) 6-10 of the WT1 gene, which includes the termination codon. This deletion extends beyond the assayed region for this gene and therefore may encompass additional genes. While this deletion is not anticipated to lead to nonsense mediated decay, it is expected to alter mRNA translation or result in a truncated protein product.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
              <MethodAttribute>
                <Attribute Type="StructVarMethodType">Read depth</Attribute>
              </MethodAttribute>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000011.9:g.(?_32410601)_(32421600_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease" multipleConditionExplanation="Uncertain">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN033288" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0950121" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN206326" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0950122" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14505471</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="9835202" TraitType="Disease" MappingType="XRef" MappingValue="C0950122" MappingRef="MedGen">
        <MedGen CUI="C0950122" Name="Frasier syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="9835202" TraitType="Disease" MappingType="XRef" MappingValue="CN033288" MappingRef="MedGen">
        <MedGen CUI="CN033288" Name="Wilms tumor 1" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="9835202" TraitType="Disease" MappingType="XRef" MappingValue="C0950121" MappingRef="MedGen">
        <MedGen CUI="C0950121" Name="Drash syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="9835202" TraitType="Disease" MappingType="XRef" MappingValue="CN206326" MappingRef="MedGen">
        <MedGen CUI="C0206115" Name="11p partial monosomy syndrome" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

